Seaborn Hunt, MD
Ophthalmology · Ocala, FLNPI 1700826922
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $928 and has fallen 59.7% since, to $374 in 2025.
Across 129 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kala Pharmaceuticals, Inc.$555
- Bausch & Lomb, A Division Of Bausch Health US, LLC$537
- Alcon$309
- AbbVie$228
- Glaukos Corporation$191
- Sight Sciences, Inc.$188
- plus $1K from 22 others
Across 44 payments — averaging $752.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$33K
What the payments were for
- Food & beverage$3,363100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kala Pharmaceuticals, Inc. | 4 | $555 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 26 | $537 |
| Alcon | 14 | $309 |
| AbbVie(2 entities) | 12 | $228 |
| Glaukos Corporation | 8 | $191 |
| Sight Sciences, Inc. | 11 | $188 |
| Sun Pharmaceutical Industries Inc. | 4 | $162 |
| Bausch & Lomb Americas Inc. | 6 | $161 |
| Tarsus Pharmaceuticals, Inc. | 5 | $158 |
| Novartis | 7 | $153 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $103 |
| Ocular Therapeutix, Inc. | 5 | $95 |
| Nova Eye, Inc. | 1 | $86 |
| Harrow Eye, LLC | 2 | $49 |
| Lumibird Medical Inc. | 1 | $45 |
| Shire North American Group Inc | 2 | $40 |
| Biotissue Holdings Inc. | 2 | $37 |
| Aerie Pharmaceuticals, Inc. | 2 | $35 |
| Eyevance Pharmaceuticals LLC | 2 | $35 |
| Dompe US, Inc. | 1 | $32 |
| Amgen | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| Rxsight Inc | 1 | $23 |
| NEW World Medical,inc. | 3 | $23 |
| Hologic Sales And Service, LLC | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $17 |
| Omeros Corporation | 1 | $14 |
| Alcon Research LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,363 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 57 | $77,003 |
| ProlensaBromfenac Sodium | 209 | $72,792 |
| Lotemax SmLoteprednol Etabonate | 289 | $72,527 |
| LumiganBimatoprost | 71 | $48,721 |
| XiidraLifitegrast | 23 | $32,529 |
| MoxifloxacinMoxifloxacin Hcl | 814 | $24,970 |
| RhopressaNetarsudil Mesylate | 23 | $12,037 |
| Cyclosporine | 12 | $10,020 |
| Travoprost | 57 | $9,095 |
| Latanoprost | 662 | $8,809 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 16 | $8,641 |
| Brinzolamide | 32 | $7,654 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $6,540 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 20 | $4,716 |
| Timolol Maleate | 259 | $3,260 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Lotemax Sm | $537 | $145,320498 claims |
| AbbVieRestasis, Lumigan, Combigan | $228 | $132,264144 claims |
| Bausch & Lomb Americas Inc.Xiidra | $161 | $32,52923 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $35 | $12,03723 claims |
| AlconSimbrinza | $309 | $8,64116 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Ocala
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.